Skip to main content
Download PDF

The beneficial effects of simultaneous supplementation of Lactobacillus reuteri and calcium fluoride nanoparticles on ovariectomy-induced osteoporosis

BMC Complementary Medicine and Therapies volume 23, Article number: 340 (2023) Cite this article

Abstract

Background

The development of new strategies to inhibit and/or treat osteoporosis as a chronic systemic disease is one of the most crucial topics. The present study aimed to investigate the simultaneous effects of calcium fluoride nanoparticles (CaF2 NPs) and lactobacillus reuteri ATCC PTA 6475 (L. reuteri) against osteoporosis in an ovariectomized rat model (OVX).

Methods

In this study, 18 matured Wistar female rats were randomly assigned into 6 groups, including control, OVX, sham, OVX + L. reuteri, OVX + CaF2 NPs, and OVX + L. reuteri + CaF2 NPs. We used OVX rats to simulate post-menopausal osteoporosis, and the treatments were begun two weeks before OVX and continued for four weeks. All groups’ blood samples were collected, and serum biomarkers (estrogen, calcium, vitamin D3, and alkaline phosphatase (ALP)) were measured. The tibia and Femur lengths of all groups were measured. Histopathological slides of tibia, kidney, and liver tissues were analyzed using the Hematoxylin and Eosin staining method.

Results

Our results revealed that dietary supplementation of L. reuteri and CaF2 NPs in low doses for 6 weeks did not show adverse effects in kidney and liver tissues. The tibial and femoral lengths of OVX rats as well as the population of osteoblasts and osteocytes and newly generated osteoid in the tibia remarkably increased in the combination therapy group. Moreover, there was a significant increase in serum estrogen levels and a significant decrease in serum calcium and alkaline phosphatase levels in combination treatment groups compared to the OVX groups not receiving the diet.

Conclusions

Our results suggest the favorable effects of the simultaneous supplementation of L. reuteri and CaF2 NP to reduce post-menopausal bone loss.

Graphical abstract

Peer Review reports

Introduction

Osteoporosis is one of the major life-threatening diseases that impact over 200 million people worldwide and mostly affects women [1]. This skeletal disorder is identified by diminished bone strength, low bone mass, and deterioration of bone tissue, leading to an increased risk of fractures [2]. Aging and the associated increase in reactive oxygen species (ROS) cause an imbalance between reabsorption and bone formation rate, resulting in an increased risk of osteoporosis [3]. Postmenopausal women experience a rapid phase of bone mass reduction due to ovarian malfunction and estrogen deficiency, as a result, the bone fracture rate in women is 2 to 3 fold higher than in men [2]. Loss of estrogens or androgens reduces defense against oxidative stress in bone, resulting in enhanced bone resorption [4].

For the prevention of osteoporosis, it has been recommended for elderlies to take daily doses of 1200–1500 mg of calcium and 400–800 IU of vitamin D3 as they should be taken concurrently. Nowadays, several therapeutic strategies for osteoporosis are presented, such as anabolic and catabolic treatments and treatments using biomolecules and biomaterials [5,6,7,8]. However, most of the medications used for osteoporosis treatment show several adverse effects. For example, bisphosphonates are the most effective class of drugs in the treatment and prevention of osteoporosis. However, this class of drugs also has side effects, including gastrointestinal complications such as gastritis or esophageal inflammation, abdominal pain, nausea, diarrhea, and constipation [9]. In addition, bisphosphonates can inhibit osteoclast activity resulting in abnormal bone remodeling that can lead to irregular femur fractures or osteonecrosis of the jaw in some patients [1]. Another more effective treatment for inhibiting bone loss is hormone replacement therapy, such as Estrogen replacement therapy (ET) and estrogen plus progesterone therapy (EPT). Estrogen-based drugs are divided into natural medicines, such as estradiol and synthetic drugs, such as ethinylestradiol. While estrogen replacement therapy can decrease the risk of bone loss and osteoporotic bone fractures during menopause, long-term use of this therapy can enhance the risk of serious illnesses such as venous thromboembolism and invasive breast cancer [1, 10]. Receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitors, such as Denosumab, reduce the risk of vertebral and hip fractures and enhance bone mineral density (BMD) across skeletal sites [11]. Despite the potential effect of Denosumab on postmenopausal women with an increased/high risk of osteoporosis, discontinuation of treatment may lead to a rapid reduction in BMD and multiple vertebral fractures [10]. Treatments based on stem cells can enhance cell lifespan and activity to reverse degenerative damage to the regeneration of bone. Despite its potential to promote bone formation, stem cell therapy has shortcomings, such as ethical issues in human research and their potential for unwanted differentiation and to suppress antitumor immune responses [12]. miRNA-based therapy as another treatment for osteoporosis showed significant potential [13]. For instance, in a study on ovariectomized (OVX) rats, the BMD of rats treated with miR-30a-3p inhibitors was significantly increased compared with the OVX group [14]. However, miRNAs might affect multiple signaling pathways that could lead to adverse effects of off-target activities [10]. Despite the existence of various drugs, the existing treatments for osteoporosis have little effect and even in some cases have a doubtful effect, which may even have a negative role in the long run. Today, as the world’s population ages, the social and economic problems of osteoporosis are on the rise. Therefore, finding a suitable treatment with fewer side effects is a priority.

Gut microbiota plays a key role in calcium and vitamin D metabolism, and also it has been proved that the gut microbiome regulates bone homeostasis in mice, potentially through modulating the immune system and osteoclast generation, proposing that modulating the microbiome and/or inflammatory tone may contribute to regulate bone mass and inhibit osteoporosis [15]. Recently, great attention has been given to the administration of probiotics which are defined as health-promoting live microorganisms and have beneficial impacts on host health and disease inhibition and/or treatment when used in enough amounts [16]. The efficacy of multiple probiotic strains in enhancing bone health has been indicated in several animal models [1]. lactobacillus reuteri (L. reuteri) is one of the nonpathogenic probiotic bacterium that produces useful immunomodulatory agents. Inflammation causes accelerated bone loss because of the induction of osteoclastogenesis and enhanced bone resorption [15]. In the human body, L. reuteri is found in different areas, such as the skin, the urinary tract, the gastrointestinal tract, and breast milk [17]. A previous study demonstrated that L. reuteri treatment significantly decreased osteoclastogenesis and bone loss in OVX mice [18]. Another study showed that L. reuteri can reduce intestinal inflammation and enhance bone density in healthy male mice [19]. Since bone is a calcium reservoir in the body in different forms, including hydroxyapatite (HA) (85%), calcium carbonate (10%), magnesium fluoride (3%), and calcium fluoride (CaF2) (3%) [20], nano-calcium supplements such as CaF2 can reduce the risk of osteoporosis. For example, the results of a study showed that injections of nano-calcium carbonate and nano-calcium citrate maintain the bone mineral density of the whole body in OVX rats [21]. Fluoride, the ionic form of fluorine, also has the greatest potential as a therapy for osteoporosis and is identified to promote osteoblast differentiation [22]. The rate of vertebral fractures in patients with postmenopausal osteoporosis was measured after receiving a combination of calcium, fluoride, and estrogen. It was found that this combination therapy is more effective for reducing vertebral fractures [23]. OVX in rats leads to bone loss related to altered immune status, like post-menopausal osteoporosis. Due to the effectiveness of the treatment performed by nanoparticles and compounds containing calcium and fluoride on osteoporosis as well as the positive effects of L. reuteri on bone health in research, this experiment was designed to determine if L. reuteri ATCC PTA 6475 and CaF2 NPs treatments protect rats from OVX-induced bone loss.

Materials and methods

Experimental design

Eighteen adult female Wistar rats (200–250 g) 6 weeks of age were obtained from the laboratory of Islamic Azad University Central Tehran Branch and applied according to laboratory animal bioethical principles and guidelines [24]. They had access to standard amounts of food, water, and space. They were also acclimated to the animal room for 1 week before the start of the experiment. The environment was maintained at 22 ± 2°C with a 12-hour light/dark cycle. The rats were fed a standard chow consisting of carbohydrate 48.8%, protein 21%, fat 3%, calcium 0.8%, phosphorus 0.4%, fibre 5%, moisture 13%, and ash 8% [18, 25]. All animal handling and procedures followed the international guidelines for the use and care of laboratory research animals and were according to the guidelines of the Institutional Animal Care and Use Committee of Islamic Azad University Central Tehran Branch. In this study, we used OVX rats to simulate post-menopausal osteoporosis and the experiment and treatments were begun two weeks before OVX and continued for four weeks. Animals were randomly divided into six groups to minimize bias; each group containing 3 rats, including Control (group 1): non-OVX untreated rats; OVX (group 2): ovariectomized untreated rats; sham (group 3): OVX rats treated with 300 µl blank solution (PBS) for experiencing gavage stress; OVX + L. reuteri (group 4): OVX rats treated with 300 µl solution, which contains 100 µl probiotic L. reuteri ATCC PTA 6475 (Takgene Zist Company, Iran) (1 × 109 colony forming units (CFU)/ml in PBS buffer and 200 µl PBS; OVX + CaF2 NPs (group 5): OVX rats treated with 300 µl solution, which contains 200 µl CaF2 NPs solution (1 mg/ml) and 100 µl PBS, and OVX + L. reuteri + CaF2 NPs (group 6): OVX rats treated with 300 µl solution, which contains 100 µl probiotic L. reuteri (1 × 109 CFU/ml) and 200 µl of CaF2 NPs solution (1 mg/ml). Oral gavage was performed with a stainless steel feeding needle for oral administration of medications in rats. This Animal research is reported in accordance with “ARRIVE” guidelines.

The bacterial solution dosage was determined according to the previous studies [18, 25, 26], which did not observe any side effects in this dose. Also, the daily CaF2 NPs dosage was chosen at 1 mg/ml, which was tested on “Vero cells” in another study and had no cytotoxic effects [27].

Calcium fluoride nanoparticles preparation

To synthesize calcium fluoride nanoparticles (CaF2 NPs) via the co-precipitation method, pure CaCl2 (Scharlau, molecular mass = 110.984) and NH4F (Merck, molecular mass = 37.036) were used [27]. Firstly, we dissolved 0.01 mol CaCl2 in 100 ml distilled water, following this, 0.02 mol of NH4F was added to the solution under vigorous stirring via a magnetic stirrer for 2 h. The mixed solution gradually transformed into an opaque white suspension during stirring. Then, the prepared suspension was centrifuged at 3000 rpm for 10 min and washed five times with Ethanol by centrifugation to eliminate the ammonium ions and the residual chloride.

Characterization of CaF2 NPs

The typical X-ray diffraction (XRD) spectra of the synthesized CaF2 NPs was determined by an X-ray diffractometer (Cu Kα line λ = 0.15406 nm). The intensity was identified in the ranges of 10° < 2θ < 90°, with 0.07° step size [28]. Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP-OES, Model: ICP-OES 730-ES, Varian) was employed to investigate the calcium content in the nanoparticles solution. The concentrations of calcium and fluoride ions in the sample were measured by X-ray fluorescence (XRF) (Philips PW1606) analysis. Dynamic light scattering (DLS) was also used to determine the hydrodynamic size of CaF2 nanoparticles using a VASCO PARTICLE SIZE ANALYZER software: NanoQ V2.5.4.0. The nanostructure of the particles was assayed by Transmission Electron Microscopy (TEM, Zeiss EM900) at an accelerating voltage of 120.0 kV. The TEM sample was prepared via coating sample onto a 200 mesh carbon-coated Cu-grid; a well-sonicated dilute suspension of sample was used in acetone to reduce agglomeration.

Surgical procedure (ovariectomy)

Osteoporosis modeling was performed on rats using a bilateral ovariectomy method. The anesthetized rodents (using xylazine and ketamine in concentrations10 mg/kg and 100 mg/kg, respectively) were laid on the surgical table and fixed by staying plaster. The bulged area on the back of the rat’s body was shaved on both sides. The skin incision site was chosen in the most bulging position on the back. A cut was made to the length of 1.5 cm on the skin to show the dorsolateral abdominal muscles. Entrance to the abdominal cavity was achieved by detaching muscles and tissues, which revealed the adipose tissue around the ovary. The upper tissues, like adipose and muscle, were pulled away until the ovary and uterine tube appeared underneath. The distal uterine horn was identified as the incision site to cut the ovarian tissue. The uterine tube was returned to the abdominal cavity, and the muscle and skin were stitched [29]. After the surgery, a morphine ampoule (5 mg/kg S.C) was injected into the rats, and they were kept in separate racks for a few days until the surgical site thoroughly healed. Also, oxytetracycline spray was used to prevent any infections [25].

Growth and body weight

Rat’s weights have been measured at the beginning of every week and the results have been compared between all the groups. At the beginning of the trial, rats weighed around 200–250 g.

Serum biochemistry parameters analysis

Blood samples were taken from the rats at the end of the treatments. About 5 mL blood sample was taken by heart tapping from each rat under anaesthetic, and then they were sacrificed instantly [30]. After clotting at room temperature for 5 min in coagulation tubes, serum samples were centrifuged for 10 min at 4000 rpm at 4 ˚C [18], and the supernatant above blood cells was collected for detection biochemical markers. Blood serum biomarkers analysis was performed according to the manufacturer’s instructions of bioassay kits for measurement of Estrogen (Estrogen (Rat) ELISA Kit K4266 BioVision, Inc), Calcium (CALCIUM ARSENAZO), Vitamin D3 (25-OH-Vitamin D KIT, Bti) and Alkaline Phosphatase (ALP, Pars Azmoon Company, Iran).

Measurement of bone length

6 weeks after the start of the treatment, the rats were sacrificed and the femur and tibia were isolated from the leg and the muscle tissues were cleaned, the sizes of both bones were determined with a digital caliper [31].

Hematoxylin and eosin (H&E) staining

Rats’ kidneys, liver, and bone were sampled. Processing of tissue samples for histological examinations followed established methods. In brief, tissue samples were rinsed with phosphate-buffered saline (PBS) and fixed in 10% formalin. Fixed tissues were embedded in paraffin, and then deparaffinized using xylene, followed by dehydration with an ethanol gradient, and rinsing with PBS twice. Molded samples were sectioned at 4 microns thickness and were stained for 3 to 5 min with hematoxylin after which they were washed with acid alcohol (1%). Afterwards, tissue slices were dehydrated in ascending grades of ethanol and were stained for 5 min with eosin. The stained tissues were dehydrated again as mentioned above, treated with dimethylbenzene, and sealed with neutral gum and at the end; slides were pictured at the focal length of 200 μm, 100 μm, and 20 μm under a light-sheet microscope. The obtained data was analyzed by persons blind to treatments.

Statistical analysis

Data are presented as mean ± standard deviation. One-way analysis of variance (ANOVA) was used to analyze the differences between the groups. This analysis was followed by Tukey’s Multiple Comparison Test. Mann-Whitney U was looked upon for histologic changes testing. Statistical analysis of data was carried out using SPSS statistic software (Version 17.0). A level of p < 0.05 was considered significant.

Results and discussion

Characterization of CaF2 nanoparticles

The phase purity and crystallinity of the synthesized CaF2 NPs were identified by the X-ray diffraction technique. Figure 1 illustrates the XRD patterns of CaF2 nanoparticles. All of the diffraction peaks can be indexed to a face-centered cubic CaF2 phase, (space group 225:Fm3 m), which is in line with the standard values for cubic CaF2 (JCPDS Card no. 87–0971) [32], confirming our product is CaF2 nanoparticles in a complete crystalline structure. The XRD pattern shows broad peaks manifesting the small crystallite size of the produced sample. This result is according to those reported in previous studies [33]. According to Fig. 2a, the concentration of metals in nanoparticle solution was determined by ICP-OES. Results showed that there were a few analogous salts with calcium that were low in volumes such as sodium and potassium and the amount of the rest of the materials is almost zero, and this indicates the purity of the synthesized nanoparticle. As shown in Fig. 2b the XRF results indicated that the only constituents of synthesized nanoparticles are calcium and fluoride, and the amount of other elements is approximately zero. The results of the DLS assay showed that the synthesized sample size is between 100 and 200 nanometers, which is acceptable for the nanoparticle (Fig. 2c). The TEM images also confirmed the results of the DLS test and the nanoscale particles with spherical morphology were identified (Fig. 3). These images show conglomerates consisting of particles of less than 40 nm in size. These agglomerations can be attributed to both the intrinsic tendency of nanoparticles to the formation of agglomerates and the quality of sample preparation for TEM assay.

Fig. 1
figure 1

X-ray diffraction (XRD) spectrum of CaF2 nanoparticles

Full size image
Fig. 2
figure 2

a) ICP-OES analysis. The amount of elements in CaF2 nanoparticles (ppm) b) XRF analysis. Percentage of elements in synthesized nanoparticle c) Hydrodynamic diameter of CaF2 nanoparticles measured by dynamic light scattering (DLS)

Full size image
Fig. 3
figure 3

Transmission electron microscopy (TEM) images of CaF2 nanoparticles at different scale bars: a) 40 nm b) 60 nm c) 80 nm d) 100 nm e) 150 nm

Full size image

Growth and body weight and tibial and femoral bone length

As shown in Fig. 4a, the weight diagram’s slope first went upward, then turned slightly downward, and then finally, their weight stabilized and maintained a slight ascending slope until the end of the trial. The reason why there is weight fluctuation at the beginning of the experiment can be the unfamiliarity of rats with the test environment and the stress caused by gavage, therefore weight fluctuation at the beginning of the study is quite normal. Bone length is a macroscopic factor that can determine decrement in bone atrophy after treatment [31]. As shown in Fig. 4 (b, c), in the control, OVX, sham, and OVX + L. reuteri groups, the length of the tibia and femur did not increase but in the OVX + CaF2 NPs and OVX + L. reuteri + CaF2 NPs, the length of the tibia (P < 0.001) and femur (P < 0.01) significantly increased compared to other groups. Therefore, our results show that L. reuteri alone has no effect on increasing bone length. However, previous studies indicated that oral administration of L. reuteri in male mice enhances bone density [34]. Another study also showed the beneficial effect of L. reuteri on increasing bone density in female mice, under an inflammatory status [35]. Fluoride ion has the therapeutic ability for osteoporosis healing and promoting osteoblast activity [36]. In this study for the first time, we investigated the influence of CaF2 nanoparticles regiments on osteoporosis. According to our results, the difference in bone growth between the two groups receiving CaF2 nanoparticles (group 5 and group 6) and other groups is statistically significant and this demonstrates that the synthesized nanoparticles can control induced osteoporosis in rats and increase bone length. A study also manifested that deficiency of calcium and fluoride can lead to adverse effects on the bone and induce bone loss [37].

Fig. 4
figure 4

a) Average weight of all groups during different weeks of study b) tibial bone length c) femoral bone length. (** P < 0.01, *** P < 0.001, **** P < 0.0001 based on oneway ANOVA, followed by Tukey’s Multiple Comparison Test)

Full size image

Histological slides of rats’ tissues

In the present study, we investigated the histological effects of L. reuteri and CaF2 NPs supplementation on kidney, liver, and bone tissues of rats using the H&E staining method.

CaF 2 NPs and L. reuteri treatment represent an increase in bone tissue regenerative cells

Bone histopathology slides (Fig. 5), show the cross-section of rat tibia bone stained with H&E. In the images of bone longitudinal sections of OVX + L. reuteri and OVX + CaF2 NPs groups, it is clear that the population of osteoblasts and osteocytes and newly generated osteoid (unmineralized bone matrix) has significantly increased compared to the OVX and sham groups, and this increase in a cell population can affect the density and longitudinal growth of bone tissue. Also, by evaluating the bone images of the OVX and sham groups, it was found that part of the bone tissue is lighter in terms of coloration, which is due to the decrease in dense areas of bone, and this is the result of the decrease in calcium deposition in the tissue and reduction of activity of osteoblasts and the rate of conversion of osteoblasts to osteocytes. By investigating the bone tissue images of the control and Ovx + probiotic + CaF2 NPs groups, bone tissue cells including osteocytes and osteoblasts were observed in dense bone tissue. In addition, the images showed that the thickness of bone tissue in the treated group was largely similar to the control group in terms of the number of bone regenerating cells. This fact largely confirms the effectiveness of the treatments. Also, a study in which OVX mice were treated with L. reuteri for 4 weeks, showed that femur and vertebral trabecular bone volumes are similar to ovary intact control mice and L. reuteri treatment suppresses bone resorption and loss associated with estrogen deficiency [18]. Another study on women between the ages of 75–80 who received an oral dose of L. reuteri showed a slight reduction in bone loss [15]. Sufficient intake of Ca is important for bone health and reduced dietary intake of Ca is related to decreased bone mass and leads to osteoporosis. A study showed that feeding of Ca and vitamin D dietary supplements has an anti-osteoporotic effect in OVX rats and leads to inducing bone formation and abolition of bone loss [38]. The positive effects of the probiotics are associated with the high content of dietary Ca and the high levels of supplemented probiotics. Probiotics indicated beneficial effects on bone metabolism via various mechanisms with extraordinary results in the animal model. The studies also demonstrated that consuming probiotics by postmenopausal women with low bone mass density increases mineral bioavailability including Ca, resulting in increasing bone mass density. Some mechanisms cause an increase in the bioavailability of the minerals, including (1) hydrolyzing glycoside bond food by probiotics in the intestines; (2) enhancement of solubility of minerals because of production of short-chain fatty acids; (3) decreasing intestinal inflammation followed by increasing bone mass density; (4) producing phytase enzyme by bacteria to overcome the effect of mineral depressed by phytate [39]. Therefore, treatment with a combination of probiotics and calcium nanoparticles is likely to have a greater effect on increasing bone density and reducing the degree of bone loss, as observed in the present study.

Fig. 5
figure 5

The histological light microscopy images of H&E stained sections in tibia bone of rats

Full size image

No detrimental effects were found in the liver tissue from CaF2 NPs treatment

According to histological images of OVX + L. reuteri and OVX + CaF2 NPs groups, it was found that hepatic cells had a normal appearance (Fig. 6). The percentage of cells with apoptosis in these two groups was about 5%. These results indicate that gavage of L. reuteri and CaF2 NPs did not have a detrimental effect on liver tissue function. In OVX and sham groups, it was also observed that the percentage of apoptotic hepatocytes was not different from the control group and was about 5%. These results suggest that postmenopausal osteoporosis modeling has no destructive effect on liver tissue. In the OVX + L. reuteri + CaF2 NPs group, hepatocytes were observed in the form of normal and hepatic plates. Hepatic sinusoids from the lobule to the central vein of the lobule were observed at intervals between the hepatic plates. A hepatic triad was observed around the lobule and in the center of each central venous lobule. The percentage of apoptotic hepatocytes in this group was less than 5%. No nanoparticle deposition was observed in liver tissues.

Fig. 6
figure 6

The histological light microscopy images of H&E stained sections in liver of rats

Full size image

The glomeruli and medulla of the treatment receiving groups were intact and normal

As shown in Fig. 7, histological renal slides show the longitudinal section of rat kidney tissue. In the three main experimental groups, including OVX + L. reuteri, OVX + CaF2 NPs, and OVX + L. reuteri + CaF2 NPs groups, there were no glomerular disease states and the capsule spaces were normal. The percentage of lymphocytes in the tissues in treated groups did not change compared to the control group. In proximal tubules and distal tubules, epithelial cells were observed normally. These results indicate that the gavage of L. reuteri solution and synthesized nanoparticles did not have a detrimental effect on renal tissue function. Based on tissue slides of OVX and sham groups, it was found that the size of renal glomeruli did not change compared to normal and a slight hemorrhage was observed at some points inside Bowman’s capsule. In these two groups, there was no change in the number of lymphocyte cells in the tissue compared to the control group. Also in proximal tubules and distal tubules, epithelial cells were observed normally. These results indicate that the infertility modeling and ovariectomy did not have a negative effect on kidney tissue. Moreover, no nanoparticle deposition was observed in the kidney tissues of the treatment groups.

Fig. 7
figure 7

The histological light microscopy images of H&E stained sections in kidney of rats

Full size image

Serological results

After 6 weeks of treatment, blood was collected from all groups of rats and after clotting at room temperature for 5 min serum samples were centrifuged for 10 min at 4000 rpm at 4 ˚C [18] and the supernatant above blood cells was collected for the detection of biochemical markers, including estrogen, calcium, vitamin D, and ALP.

CaF2 NPs and L. reuteri each alone raised the level of serum estrogen level to some extent, but the simultaneous treatment was able to create a significant difference

Estrogen influences bone tissue through the different mechanisms, including (i) inducing the generation of calcitonin, so preventing bone resorption, (ii) reducing the sensitivity of bone mass to parathyroid hormone, so decreasing bone resorption, (iii) diminishing the calcium excretion from the kidney, (iv) increasing calcium resorption via the intestine, and (v) direct effects on bone through the estrogen receptors [40]. Estrogen deficiency disrupts the normal bone turnover cycle at menopause and causes an irregular increase in bone resorption as compared with deposition [40]. In this study we assayed alters in estrogen levels in OVX rats under treatment with L. reuteri and CaF2 NPs. According to our results, as shown in Fig. 8a, in the OVX group in which rats underwent ovariectomy and didn’t receive any treatment, the amount of estrogen has significantly decreased compared with the control group (P < 0.001), and this is also true for the sham group which received a blank solution (P < 0.001). In OVX + L. reuteri and OVX + CaF2 NPs groups, estrogen levels increased almost the same amount, which was significant compared to the groups without treatment (P < 0.05). The combination therapy in the OVX + L. reuteri + CaF2 NPs group also showed a significant increase in estrogen levels compared to the sham and OVX groups (P < 0.01). The predominant metabolism of estrogens, including hydroxylation and conjugation, takes place in the liver. Conjugated estrogens go through the enterohepatic circulation to the bile and ultimately pass into the small intestine, where they are deconjugated by the gut microbiome and are partially reabsorbed, and enter the circulation through the portal vein [41]. According to a hypothesis, this enterohepatic recirculation impacts the systemic levels and half-life of estrogens in men and postmenopausal women, and probably during the luteal phase in premenopausal women. The diversity of the gut microbiome could influence systemic estrogen levels by different processes [42]. L. reuteri is one of the indigenous bacteria in the gastrointestinal tract of humans and animals [43]. Previous studies have indicated the modulatory impacts of L. reuteri on the microbiotas of piglets, rodents, and humans [17]. Therefore, according to these findings, we concluded that L. reuteri probiotic by modulating the gut microbiome may regulate serum estrogen levels. In addition, a more recent study in agreement with our results showed that calcium supplementation elevated the estradiol content level in OVX rats [44]. They proposed that the beneficial impacts of calcium supplementation on bone loss may be partially associated with the enhancement in the level of estrogen and stimulation of the changes in levels of metabolite, resulting in increasing the bone mineral density.

Fig. 8
figure 8

Evaluation of biochemical parameters in experimental groups. a) serum estrogen level. b) serum vitamin D3 level. (* P < 0.05, ** P < 0.01, *** P < 0.001 based on oneway ANOVA, followed by Tukey’s Multiple Comparison Test)

Full size image

Simultaneous CaF2 NPs and L. reuteri treatment had a slight impact on the serum vitamin D3 levels regulation

The deficiency of serum vitamin D levels among postmenopausal women with osteoporosis is widely prevalent [45]. As shown in Fig. 8b, our results also showed a significant reduction in serum vitamin D3 levels in the OVX (P < 0.01), sham (P < 0.05), OVX + L. reuteri (P < 0.05), and OVX + CaF2 NPs (P < 0.05) groups compared with the control group. Treatment with L. reuteri and CaF2 NPs alone in our study didn’t show a significant benefit for increasing serum vitamin D3 levels in OVX rats. However, the combination therapy in the OVX + L. reuteri + CaF2 NPs group showed a slight increase in serum vitamin D3 level, which, perchance if the test time was longer, the level of vitamin D3 would even reach almost normal levels. In line with our results, previous findings showed that circulating 25-hydroxyvitamin D level increases in response to oral L. reuteri NCIMB 30,242 probiotic supplementation [46]. Another study also suggested that prebiotic supplementation can increase provitamin D3 biosynthesis [47]. Moreover, according to previous studies receiving calcium can increase the mean serum concentration of 25-hydroxyvitamin D3 [48]. Jorde et al. also reported that in the females, which have low vitamin D intake (< 7 µg/d) there is a significant increase in serum 25-hydroxyvitamin D3 level with increasing calcium intake [49].

Serum calcium levels in the receiving L. reuteri and combination of L. reuteri and CaF2 NPs treatment groups significantly decreased

According to our results (Fig. 9a), the OVX and sham groups, which are osteoporosis models, showed a significant increase in serum calcium levels compared with the control group (P < 0.001). Previous studies also showed that in the OVX mouse, intestinal calcium malabsorption occurs in postmenopausal osteoporosis, and ovariectomy caused a significant increase in fecal and urinary calcium and a significant decrease in calcium absorption [50]. Interestingly, enhanced calcium absorption by some probiotic bacteria such as Lactobacillus salivarius was indicated in Caco-2 cells [39]. L. reuteri probiotic can also increase calcium uptake by elevating calcium solubility [39]. Another study on L. reuteri, Lactobacillus casei, and Lactobacillus gasseri reported more calcium absorption and 35% higher bone weight between the probiotic-fed group compared with the control group in rat models [51]. Our results also showed L. reuteri in OVX + L. reuteri group significantly decreases serum calcium levels compared to the sham group (P < 0.05), which may be due to the increasing calcium absorption. CaF2 NPs alone in the OVX + CaF2 NPs group showed no significant effect on decreasing the serum calcium level compared to the sham and OVX as osteoporosis model groups. However, in the OVX + L. reuteri + CaF2 NPs group a significant reduction in the serum calcium level was observed compared to the OVX and sham groups (P < 0.01). By comparing the combination treatment group and the control group and considering their similarity in serum calcium levels, it was concluded that the combination therapy had a significant effect on calcium absorption and the return of serum calcium levels almost to the normal level. Probably, the presence of fluoride ions in this group, in addition to probiotic, helps to increase calcium absorption. Stamp et al. suggested that fluoride therapy in osteoporosis reduces the total calcium and ionized calcium concentrations, which may be due to the ‘movement’ of calcium from the circulation into tissues, such as the bone [52]. Another study also indicated that fluoride caused the reduction of calcium concentration in the serum of female rats resulting in calcium transportation to the intercellular fluid and deposition in bones and teeth [53].

Fig. 9
figure 9

Evaluation of biochemical parameters in experimental groups. a) serum calcium level. b) serum ALP level. (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 based on oneway ANOVA, followed by Tukey’s Multiple Comparison Test)

Full size image

Serum alkaline phosphatase (ALP) levels significantly decreased in the combination L. reuteri and CaF2 NPs treatment group

ALP is a membrane-bound glycoprotein that presents in many tissues in the body, with more concentrations in osteoblasts and in the liver. According to previous findings, ALP was identified as a marker of bone formation; although, more recent studies have proposed that ALP should be considered as a marker of bone turnover rather than bone formation [54,55,56]. Our results of serum ALP values in the OVX and sham groups showed a significant increase compared with the control group (P < 0.0001 and P < 0.001 respectively). A study in line with our results indicated that serum ALP level increases in the OVX-induced osteoporosis [57]. Skeletal system diseases associated with enhanced osteoblast activity and bone remodeling cause elevation of ALP level [58]. Previous studies showed that multispecies probiotic supplementation has beneficial effects on bone health due to reducing the rate of bone turnover. A recent randomized double-blind placebo-controlled clinical trial showed that ALP was significantly decreased in postmenopausal women after taking probiotic supplementation [59]. Our study also demonstrated that receiving L. reuteri probiotic significantly decreased the level of ALP compared with the OVX group (P < 0.05) (Fig. 9b). Another study also manifested that intervention with L. reuteri reduced ALP and led to diminished bone turnover [18], which is in agreement with our study. Also, group 5, which received CaF2 NPs, showed a significant decrease in serum ALP level compared with the OVX group (P < 0.01). Since appropriate doses of fluoride induce bone formation by osteoblastic stimulation, we concluded that the intake of CaF2 NPs in our study increases bone formation rate resulting in reducing serum ALP level in OVX-induced osteoporosis. Moreover, combination therapy with L. reuteri probiotic and CaF2 NPs was more effective and significantly reduced ALP levels compared with OVX and sham groups (P < 0.001 and P < 0.05 respectively).

This research was not in the absence of its shortcomings and limitations. Limitations of this work include the small sample size in each group (n = 3), the use of only one dose of the nanoparticle, and the short duration of the experiment. We suggest that long-term follow-up on a larger scale with different doses of CaF2 NPs alongside L. reuteri are needed to determine the effectiveness of these two substances simultaneously and individually.

Conclusion

In this study, for the first time, we used combined dietary supplementation with L. reuteri and CaF2 nanoparticles for attenuation of bone loss in OVX-induced osteoporosis. According to our results, daily simultaneous supplementation of low doses of L. reuteri and CaF2 NPs for 6 weeks significantly increased the length of the tibia and femur. The histological images of rat tibia tissue also showed a significant increase in the population of osteoblasts and osteocytes and increased newly generated osteoid. Interestingly, no adverse side effects on the kidney and liver were observed in the treatment groups. In addition, the combination therapy also had a beneficial effect in reducing serum Calcium and ALP levels and increasing serum Estrogen and Vitamin D3 levels. Therefore, this combined supplementation could be a new and promising approach to reducing the symptoms of post-menopausal osteoporosis. Further long-term investigations on a larger scale are needed to dissect the mechanisms and to evaluate the usefulness of simultaneous therapy with L. reuteri and CaF2 NPs for preventing bone loss in osteoporosis.

Data Availability

All data generated or analyzed during this study are included in this published article.

References

  1. Quach D, Parameswaran N, McCabe L, Britton RA. Characterizing how probiotic Lactobacillus reuteri 6475 and lactobacillic acid mediate suppression of osteoclast differentiation. Bone Rep. 2019;11:100227.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115–37.

    PubMed  CAS  Google Scholar 

  3. Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46.

    Article  PubMed  Google Scholar 

  4. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010;31(3):266–300.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Tonk CH, Shoushrah SH, Babczyk P, Khaldi-Hansen E, Schulze M, Herten M, et al. Therapeutic treatments for osteoporosis—which combination of Pills is the best among the bad? Int J Mol Sci. 2022;23(3):1393.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Niknam Z, Zali H, Mansouri V, Tavirani MR, Omidi M. Morphological and molecular analysis of osteoblasts differentiated from mesenchymal stem cells in polycaprolactone/magnesium oxide/graphene oxide scaffold. Int J Organ Transplantation Med. 2019;10(4):171.

    CAS  Google Scholar 

  7. Niknam Z, Golchin A, Rezaei–Tavirani M, Ranjbarvan P, Zali H, Omidi M, et al. Osteogenic differentiation potential of adipose-derived mesenchymal stem cells cultured on magnesium oxide/polycaprolactone nanofibrous scaffolds for improving bone tissue reconstruction. Adv Pharm Bull. 2020;12(1):142–54.

    PubMed  PubMed Central  Google Scholar 

  8. Niknam Z, Hosseinzadeh F, Shams F, Fath-Bayati L, Nuoroozi G, Mohammadi Amirabad L, et al. Recent advances and challenges in graphene‐based nanocomposite scaffolds for tissue engineering application. J Biomedical Mater Res Part A. 2022;110(10):1695–721.

    Article  CAS  Google Scholar 

  9. Lin JT, Lane JM. Osteoporosis: a review. Clin Orthop Relat Research®. 2004;425:126–34.

    Article  Google Scholar 

  10. Liang B, Burley G, Lin S, Shi Y-C. Osteoporosis pathogenesis and treatment: existing and emerging avenues. Cell Mol Biol Lett. 2022;27(1):72.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Deeks ED. Denosumab: a review in postmenopausal osteoporosis. Drugs Aging. 2018;35:163–73.

    Article  PubMed  CAS  Google Scholar 

  12. Paspaliaris V, Kolios G. Stem cells in osteoporosis: from biology to new therapeutic approaches. Stem Cells International. 2019;2019.

  13. Hadjiargyrou M, Komatsu DE. The therapeutic potential of microRNAs as orthobiologics for skeletal fractures. J Bone Miner Res. 2019;34(5):797–809.

    Article  PubMed  Google Scholar 

  14. Liu H, Hao D, Wang X, Hu H, Li Y, Dong X. MiR-30a-3p promotes ovariectomy-induced osteoporosis in rats via targeting SFRP1. Eur Rev Med Pharmacol Sci. 2019;23(22):9754–60.

    PubMed  Google Scholar 

  15. Nilsson A, Sundh D, Bäckhed F, Lorentzon M. Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double‐blind, clinical trial. J Intern Med. 2018;284(3):307–17.

    Article  PubMed  CAS  Google Scholar 

  16. Kunes M, Kvetina J, Probiotics. Preclinical testing for Verification of their gastrointestinal effectiveness. Nutraceuticals: Elsevier; 2016. pp. 799–810.

    Google Scholar 

  17. Mu Q, Tavella VJ, Luo XM. Role of Lactobacillus reuteri in human health and diseases. Front Microbiol. 2018;9:757.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Britton RA, Irwin R, Quach D, Schaefer L, Zhang J, Lee T, et al. Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model. J Cell Physiol. 2014;229(11):1822–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. McCabe LR, Irwin R, Schaefer L, Britton RA. Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice. J Cell Physiol. 2013;228(8):1793–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Tripathy N, Perumal E, Ahmad R, Song JE, Khang G. Hybrid composite biomaterials. Principles of Regenerative Medicine. Elsevier; 2019. pp. 695–714.

  21. Huang S, Chen JC, Hsu CW, Chang WH. Effects of nano calcium carbonate and nano calcium citrate on toxicity in ICR mice and on bone mineral density in an ovariectomized mice model. Nanotechnology. 2009;20(37):375102.

    Article  PubMed  Google Scholar 

  22. Fookes FA, Mengatto LN, Rigalli A, Luna JA. Controlled fluoride release for osteoporosis treatment using orally administered chitosan hydrogels. J Drug Deliv Sci Technol. 2019;51:268–75.

    Article  CAS  Google Scholar 

  23. Riggs BL, Seeman E, Hodgson SF, Taves DR, O’Fallon WM. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: comparison with conventional therapy. N Engl J Med. 1982;306(8):446–50.

    Article  PubMed  CAS  Google Scholar 

  24. Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. The 1996 guide for the care and use of laboratory animals. ILAR J. 1997;38(1):41–8.

    Article  PubMed  Google Scholar 

  25. Montazeri-Najafabady N, Ghasemi Y, Dabbaghmanesh MH, Ashoori Y, Talezadeh P, Koohpeyma F, et al. Exploring the bone sparing effects of postbiotics in the post-menopausal rat model. BMC Complement Med Ther. 2021;21(1):155.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Montazeri-Najafabady N, Ghasemi Y, Dabbaghmanesh MH, Talezadeh P, Koohpeyma F, Gholami A. Supportive role of probiotic strains in protecting rats from ovariectomy-induced cortical bone loss. Probiotics and Antimicrobial Proteins. 2019;11:1145–54.

    Article  PubMed  CAS  Google Scholar 

  27. Bala WA, Benitha V, Jeyasubramanian K, Hikku G, Sankar P, Kumar SV. Investigation of anti-bacterial activity and cytotoxicity of calcium fluoride nanoparticles. J Fluorine Chem. 2017;193:38–44.

    Article  CAS  Google Scholar 

  28. Nakhaei O, Shahtahmassebi N, Rezaeeroknabadi M, Mohagheghi MB. Synthesis, characterization and study of optical properties of polyvinyl alcohol/CaF2 nanocomposite films. Scientia Iranica. 2012;19(6):1979–83.

    Article  Google Scholar 

  29. Park SB, Lee YJ, Chung CK. Bone mineral density changes after ovariectomy in rats as an osteopenic model: stepwise description of double dorso-lateral approach. J Korean Neurosurg Soc. 2010;48(4):309.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Chargui I, Grissa I, Bensassi F, Hrira MY, Haouem S, Haouas Z, et al. Oxidative stress, biochemical and histopathological alterations in the liver and kidney of female rats exposed to low doses of deltamethrin (DM): a molecular assessment. Biomed Environ Sci. 2012;25(6):672–83.

    PubMed  CAS  Google Scholar 

  31. Lepola V, Jalovaara P, Väänänen K. The influence of clodronate on the torsional strength of the growing rat tibia in immobilization osteoporosis. Bone. 1994;15(3):367–71.

    Article  PubMed  CAS  Google Scholar 

  32. Tahvildari K, ESMAEILI PM, Ghammamy S, Nabipour H. CaF2 nanoparticles: synthesis and characterization. 2012.

  33. Alharbi ND. Size controlled CaF2 nanocubes and their dosimetric properties using photoluminescence technique. Journal of Nanomaterials. 2015;2015.

  34. Collins FL, Rios-Arce ND, Schepper JD, Jones AD, Schaefer L, Britton RA, et al. Beneficial effects of Lactobacillus reuteri 6475 on bone density in male mice is dependent on lymphocytes. Sci Rep. 2019;9(1):1–17.

    Article  Google Scholar 

  35. Collins FL, Irwin R, Bierhalter H, Schepper J, Britton RA, Parameswaran N, et al. Lactobacillus reuteri 6475 increases bone density in intact females only under an inflammatory setting. PLoS ONE. 2016;11(4):e0153180.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Azami M, Jalilifiroozinezhad S, Mozafari M, Rabiee M. Synthesis and solubility of calcium fluoride/hydroxy-fluorapatite nanocrystals for dental applications. Ceram Int. 2011;37(6):2007–14.

    Article  CAS  Google Scholar 

  37. Spencer H, Kramer L. Osteoporosis: calcium, fluoride, and aluminum interactions. J Am Coll Nutr. 1985;4(1):121–8.

    Article  PubMed  CAS  Google Scholar 

  38. Mustafa RA, Alfky NA, Hijazi HH, Header EA, Azzeh FS. Biological effect of calcium and vitamin D dietary supplements against osteoporosis in ovariectomized rats. Prog Nutr. 2018;20(1):86–93.

    CAS  Google Scholar 

  39. Parvaneh K, Jamaluddin R, Karimi G, Erfani R. Effect of probiotics supplementation on bone mineral content and bone mass density. Sci World J. 2014;2014.

  40. Ji M-X, Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Translational Med. 2015;1(01):9–13.

    Article  Google Scholar 

  41. Chen KLA, Liu X, Zhao YC, Hieronymi K, Rossi G, Auvil LS, et al. Long-term administration of conjugated estrogen and bazedoxifene decreased murine fecal β-glucuronidase activity without impacting overall microbiome community. Sci Rep. 2018;8(1):1–11.

    Google Scholar 

  42. Flores R, Shi J, Fuhrman B, Xu X, Veenstra TD, Gail MH, et al. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Translational Med. 2012;10(1):1–11.

    Article  Google Scholar 

  43. Sinkiewicz G. Lactobacillus reuteri in Health and Disease. Malmö University; 2010.

  44. Mao H, Wang W, Shi L, Chen C, Han C, Zhao J, et al. Metabolomics and physiological analysis of the effect of calcium supplements on reducing bone loss in ovariectomized rats by increasing estradiol levels. Nutr Metabolism. 2021;18(1):1–14.

    Article  Google Scholar 

  45. Suganthan N, Kumanan T, Kesavan V, Aravinthan M, Rajeshkannan N. Vitamin D status among postmenopausal osteoporotic women: a hospital based cross-sectional study from Northern Sri Lanka. BMC Nutr. 2020;6(1):1–8.

    Article  Google Scholar 

  46. Jones ML, Martoni CJ, Prakash S. Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial. J Clin Endocrinol Metabolism. 2013;98(7):2944–51.

    Article  CAS  Google Scholar 

  47. Gokhale S, Bhaduri A. Provitamin D3 modulation through prebiotics supplementation: simulation based assessment. Sci Rep. 2019;9(1):1–8.

    Article  Google Scholar 

  48. Berlin T, Björkhem I. Effect of calcium intake on serum levels of 25-hydroxyvitamin D3. Eur J Clin Invest. 1988;18(1):52–5.

    Article  PubMed  CAS  Google Scholar 

  49. Jorde R, Grimnes G. Increased calcium intake is associated lower serum 25-hydroxyvitamin D levels in subjects with adequate vitamin D intake: a population-based observational study. BMC Nutr. 2020;6(1):1–9.

    Article  Google Scholar 

  50. Kalu DN, Chen C. Ovariectomized murine model of postmenopausal calcium malabsorption. J Bone Miner Res. 1999;14(4):593–601.

    Article  PubMed  CAS  Google Scholar 

  51. Ghanem K, Badawy I, Abdel-Salam A. Influence of yoghurt and probiotic yoghurt on the absorption of calcium, magnesium, iron and bone mineralization in rats. Milchwissenschaft. 2004;59(9–10):472–5.

    CAS  Google Scholar 

  52. Stamp TC, Jenkins MV, Loveridge N, Saphier PW, Katakity M, MacArthur SE. Fluoride therapy in osteoporosis: Acute effects on parathyroid and mineral homoeostasis. Clin Sci. 1988;75(2):143–6.

    Article  CAS  Google Scholar 

  53. Fočak M, Hasković E, Suljević D. The effect of fluoride on the serum level of calcium in the rat (Rattus norvegicus). Archives of Biological Sciences. 2012;64(4):1585–9.

    Article  Google Scholar 

  54. Azinge E, Bolarin D. Osteocalcin and bone-specific alkaline phosphatase in sickle cell haemoglobinopathies. Nigerian J Physiological Sci. 2006;21:1–2.

    Google Scholar 

  55. Hooshmand S, Chai SC, Saadat RL, Payton ME, Brummel-Smith K, Arjmandi BH. Comparative effects of dried plum and dried apple on bone in postmenopausal women. Br J Nutr. 2011;106(6):923–30.

    Article  PubMed  CAS  Google Scholar 

  56. Wang J, Pei F, Tu C, Zhang H, Qiu X. Serum bone turnover markers in patients with primary bone tumors. Oncology. 2007;72(5–6):338–42.

    Article  PubMed  CAS  Google Scholar 

  57. Grigoryan AV, Dimitrova AA, Kostov KG, Russeva AL, Atanasova MA, Blagev AB, et al. Changes of serum concentrations of alkaline phosphatase and metalloproteinase-9 in an ovariectomized wistar rat model of osteoporosis. J Biomedical Clin Res. 2017;10(1):32–6.

    Article  Google Scholar 

  58. Kim SK, Lee MH, Rhee MH. Studies on the effects of biomedicinal agents on serum concentration of Ca2+, P and ALP activity in osteoporosis-induced rats. J Vet Sci. 2003;4(2):151–4.

    Article  PubMed  Google Scholar 

  59. Jafarnejad S, Djafarian K, Fazeli MR, Yekaninejad MS, Rostamian A, Keshavarz SA. Effects of a multispecies probiotic supplement on bone health in osteopenic postmenopausal women: a randomized, double-blind, controlled trial. J Am Coll Nutr. 2017;36(7):497–506.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Islamic Azad University Central Tehran Branch.

Funding

This research received no specific grant from any funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Author notes

  1. Dibachehr Rahmani and Bahareh Faal contributed equally to the work.

Authors and Affiliations

  1. Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran

    Dibachehr Rahmani, Bahareh Faal & Saeed Hesami Tackallou

  2. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Hakimeh Zali

  3. Neurophysiology Research Center, Cellular and Molecular Medicine research Institute, Urmia University of Medical Sciences, Urmia, Iran

    Zahra Niknam

Authors
  1. Dibachehr Rahmani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bahareh Faal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hakimeh Zali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Saeed Hesami Tackallou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zahra Niknam
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All of the authors contributed significantly to the work. DR and BF carried out the experimental research and assisted in the preparation of the paper. HZ, SHT, and ZN assisted in developing the idea of the study and revised the work critically for intellectual content. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Saeed Hesami Tackallou or Zahra Niknam.

Ethics declarations

Ethics approval and consent to participate

All methods of this study was approved by the ethics committee of Islamic Azad University Central Tehran Branch (IR.IAU.CTB.REC.1400.037).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rahmani, D., Faal, B., Zali, H. et al. The beneficial effects of simultaneous supplementation of Lactobacillus reuteri and calcium fluoride nanoparticles on ovariectomy-induced osteoporosis. BMC Complement Med Ther 23, 340 (2023). https://doi.org/10.1186/s12906-023-04167-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-023-04167-6

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us